Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
This triple-action mechanism distinguishes it from existing agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP receptor agonist), and may offer enhanced effects on weight reduction and metabolic regulation, though the full clinical profile is still being established
PMID 2324091
Understanding the consequences of storage errors helps patients recognise when medication replacement may be necessary
Several new opportunities are under evaluation due to recent promising discoveries in molecular and cell biology
In early studies, retatrutide helped people lose weight
Semaglutide (Wegovy) is given once weekly, while liraglutide (Saxenda) requires daily administration
US$ 24.91
US$ 25.85
US$ 28.04
